Print

Purpose

This feasibility study collects initial data on the use of an fMRI neurofeedback protocol for treating anhedonia in methadone-treated individuals with opioid use disorder (OUD). The intervention tested has previously been shown to reduce anhedonia in individuals with depression and this study is collecting first-in-human data in an OUD population. Investigators will assess tolerability of the intervention and collect preliminary data from 2-3 subjects monitoring changes in anhedonia, non-substance-related autobiographical memory recall, and meaning in life.

Condition

Eligibility

Eligible Ages
Between 18 Years and 50 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • ≥3 months of methadone treatment for OUD - Presence of anhedonia, as assessed via SHAPS - Baseline autobiographical memory deficit, as assessed via AMT

Exclusion Criteria

  • Failure to pass an MRI screening - Women who are pregnant - Psychosis, as assessed via Yale PRIME Early Psychosis Screening Test - Serious suicidal ideation - Serious medical condition - Legally blind

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Individuals with OUD 		Participants will complete five study visits. They will receive neurofeedback at two separate scanning sessions (sessions 2-3). Neurofeedback scans will include rest, neurofeedback, and transfer (i.e., no feedback) runs, one week apart.
  • Device: real-time functional magnetic resonance imaging (rt-fMRI) neurofeedback
    A non-invasive, non-pharmacological therapeutic tool that enables an individual to learn to modulate their neural activity in order to effect behavioral change.

Recruiting Locations

APT Foundation
New Haven, Connecticut 06520

More Details

Status
Recruiting
Sponsor
Yale University

Study Contact

Sarah Paprotna
+1 (203) 737-5994
sarah.paprotna@yale.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.